

MOL #66357

AChR $\alpha 5$ Subunit Variant Associated With Risk for Nicotine Dependence and Lung Cancer
Reduces $(\alpha 4\beta 2)_2\alpha 5$ AChR Function

Alexander Kuryatov, Wade Berrettini, and Jon Lindstrom

Department of Neuroscience, University of Pennsylvania Medical School,
Philadelphia, Pennsylvania (A.K., J.L.)

Department of Psychiatry, University of Pennsylvania Medical School,
Philadelphia, Pennsylvania (W.B.)

MOL #66357

Running Title:

Nicotine and $\alpha 5$ AChR Function

Corresponding author:

Jon Lindstrom

Department of Neuroscience

Medical School of the University of Pennsylvania

Philadelphia, Pennsylvania

19104-6074

Phone: (215) 573-2859

Fax: (215) 573-2858

Email: JSLKK@mail.med.upenn.edu

Pages: 29

Tables: 1

Figures: 3

References: 36

Word number in

Abstract: 248

Introduction: 739

Discussion: 1106

Abbreviations: AChR, nicotinic acetylcholine receptor; ACh, acetylcholine; PAM, positive allosteric modulator

MOL #66357

ABSTRACT

Genomic studies have identified a D398N variation in the $\alpha 5$ subunit of nicotinic acetylcholine receptors (AChRs) which increases risk of nicotine dependence and lung cancer. $(\alpha 4\beta 2)_2\alpha 5$ AChRs are a significant brain presynaptic subtype in brain. Their high sensitivity to activation by nicotine and high Ca^{++} permeability give them substantial functional impact. $\alpha 3\beta 4^*$ and $\alpha 3\beta 2^*$ AChRs are predominant postsynaptic AChRs in the autonomic nervous system, but rare in brain. The amino acid 398 of $\alpha 5$ is located in the large cytoplasmic domain near the amphipathic α helix preceding the M4 transmembrane domain. These helices have been shown to influence AChR conductance by forming portals to the central channel. We report that $\alpha 5$ N398 lowers Ca^{++} permeability and increases acute desensitization in $(\alpha 4\beta 2)_2\alpha 5$, but not in $(\alpha 3\beta 4)_2\alpha 5$ or $(\alpha 3\beta 2)_2\alpha 5$ AChRs. This suggests that a positive allosteric modulator (PAM) would augment nicotine replacement therapy for those with this risk variant. $\alpha 5$ D398N variation does not alter sensitivity to activation. The high sensitivity to activation and desensitization of $(\alpha 4\beta 2)_2\alpha 5$ AChRs by nicotine results in a narrow concentration range in which activation and desensitization curves overlap. This region centers on 0.2 μM nicotine, a concentration typically sustained in smokers. This concentration would desensitize 60% of these AChRs and permit smoldering activation of the remainder. The low sensitivity to activation and desensitization of $(\alpha 3\beta 4)_2\alpha 5$ AChRs by nicotine results in a broad region of overlap centered near 10 μM . Thus, at the nicotine concentrations in smokers, negligible activation or desensitization of this subtype would occur.

MOL #66357

Introduction

Genome wide association studies have identified sequence variants in the region encoding $\alpha 3$, $\beta 4$, and $\alpha 5$ subunits of nicotinic acetylcholine receptors (AChRs) which increase risks of nicotine dependence and, probably thereby, lung cancer (Berrettini et al., 2008; Bierut et al., 2008; Wang et al., 2009; Saccone et al., 2009; Weiss et al., 2008; Thorgeirsson et al., 2008; Hung et al., 2008; Amos et al., 2008). Only one of these causes a change in amino acid sequence, the $\alpha 5$ variation D398N. N is the risk variant. It reduced the response to epibatidine of $(\alpha 4\beta 2)_2\alpha 5$ AChRs assayed using Ca^{++} flux (Bierut et al., 2008).

$\alpha 5^*$ AChRs are important in brain. $(\alpha 4\beta 2)_2\alpha 5$ AChRs are a significant presynaptic subtype comprising 10-37% of total $\alpha 4\beta 2^*$ AChRs, depending on the brain region (Brown et al., 2007; Mao et al., 2008). Their high sensitivity to activation by nicotine and high Ca^{++} permeability give them substantial functional impact (Brown et al., 2007; Tapia et al., 2007; Kuryatov et al., 2008; Grady et al., 2010). They are sensitive to nicotine-induced upregulation in cell culture (Kuryatov et al., 2008). In brain, upregulation was not observed (Mao et al., 2008). This may be because the amount of $\alpha 5$ was limiting. $\alpha 5$ assembles very avidly with $\alpha 4\beta 2$ (Kuryatov et al., 2008). Partially assembled pools of subunits are susceptible to the pharmacological chaperone effects of nicotine that account for rapidly increased AChR assembly in the presence of nicotine (Kuryatov et al., 2005). Excess $\alpha 5$ results in formation of dead end intermediates that cannot assemble into mature AChRs (e.g. $\alpha 5\alpha 4\beta 2\alpha 5$) (Kuryatov et al., 2008). Transfected cells which express sufficient excess $\alpha 5$ or $\beta 3$ to express only $(\alpha 4\beta 2)_2\alpha 5$ or $(\alpha 4\beta 2)_2\beta 3$ AChRs accumulate dead end intermediates, have unusual morphologies, and grow slowly. The amount of $\alpha 5$ in brain may be limited to avoid forming dead end intermediates.

$\alpha 3\beta 4^*$ and $\alpha 3\beta 2^*$ AChRs are rare in the brain, except in the medial habenula (Salas et al., 2009; Gotti et al., 2007). They are predominant postsynaptic AChRs in the autonomic

MOL #66357

nervous system (Xu et al., 1999). Human $\alpha 3\beta 2^*$, but not the more predominant $\alpha 3\beta 4^*$ AChRs, are sensitive to nicotine-induced upregulation (Wang et al., 1998). $\alpha 5$ subunits increase the Ca^{++} permeability and desensitization rates of these subtypes (Gerzanich et al., 1998). $\alpha 5$ increases sensitivity to nicotine activation of $\alpha 3\beta 2$ but not $\alpha 3\beta 4$ AChRs (Gerzanich et al., 1998).

The $\alpha 5$ amino acid 398 is in the large cytoplasmic domain adjacent to the conserved amphipathic α helix that immediately precedes the M4 transmembrane domain. This is far from the extracellular location of ACh binding sites, so it is unlikely to influence the sensitivity of agonist binding. A prominent location that influences Ca^{++} permeability of $\alpha 4\beta 2^*$ AChRs is a ring of charged amino acids in the M2 transmembrane domain which lines the cation channel (Tapia et al., 2007). In that location, a negatively charged $\alpha 4$ E261 promotes Ca^{++} permeability, as does E261 of $\alpha 5$, while the positively charged $\beta 2$ K258 inhibits it. The cytoplasmic amphipathic helix has been shown to influence $\alpha 4\beta 2$ AChR conductance by forming a vestibule to the channel with lateral windows through which cations must pass (Hales et al., 2006). In such a region, the negatively charged aspartate D398 might promote Ca^{++} permeability while asparagine N398, in which the negatively charged carboxyl group of aspartate has been replaced by an amide group, might inhibit it.

We report that the $\alpha 5$ N398 high-risk variant has lower Ca^{++} permeability and acutely desensitizes more than the D398 variant in $(\alpha 4\beta 2)_2\alpha 5$, but not in $(\alpha 3\beta 4)_2\alpha 5$ or $(\alpha 3\beta 2)_2\alpha 5$ AChRs. This suggests that a positive allosteric modulator (PAM) would enhance nicotine replacement therapy for those with the N398 risk variant. A PAM might achieve the benefits of increasing the amount of $(\alpha 4\beta 2)_2\alpha 5$ AChRs without the potential liabilities of increasing the amount of $\alpha 5$.

We report that $\alpha 5$ D398N variation does not alter sensitivity to activation by nicotine. The high sensitivity to activation and desensitization of $(\alpha 4\beta 2)_2\alpha 5$ AChRs by nicotine results in a

MOL #66357

narrow concentration range in which activation and desensitization concentration/response curves overlap. This region centers on 0.2 μM , a concentration of nicotine typically sustained by smokers (Benowitz, 1996). This concentration would desensitize 60% of $(\alpha 4\beta 2)_2\alpha 5$ AChRs and permit smoldering activation of the remainder. The low sensitivity to activation and desensitization of $(\alpha 3\beta 4)_2\alpha 5$ AChRs by nicotine results in a broad region of overlap of concentration/response curves centered near 10 μM . At nicotine concentrations sustained in smokers, negligible activation or desensitization of these AChRs would occur.

MOL #66357

Materials and Methods

cDNAs and cRNAs. The cDNAs for human $\alpha 3$, $\beta 2$, and $\alpha 4$ subunits were cloned in this laboratory (Gerzanich et al., 1998; Wang et al., 1998). The cDNA for human $\alpha 5$ (D398) was kindly provided by Dr. Francesco Clementi. Synthesis of tandem constructs of $\beta 2(\text{AGS})_6\alpha 4$ and $\alpha 4(\text{AGS})_{12}\beta 2$ (Zhou et al., 2003) were described previously. Mutation N398 was introduced into the human $\alpha 5$ subunit using the QuikChange site-directed mutagenesis kit (Stratagene, La Jolla, CA) and sequenced to verify that only the desired mutation was present. To prepare the $\beta 2(\text{AGS})_6\alpha 4(\text{AGS})_{12}\beta 2(\text{AGS})_6\alpha 4$ tetrameric concatamer, $\beta 2(\text{AGS})_6\alpha 4$ was cut with Sall and Nsil, $\alpha 4(\text{AGS})_{12}\beta 2$ with Nsil and BamHI, and $\beta 2(\text{AGS})_6\alpha 4$ with BamHI and Sall. Ligation of the Sall - Nsil fragment from $\beta 2(\text{AGS})_6\alpha 4$ with the Nsil - BamHI fragment from $\alpha 4(\text{AGS})_{12}\beta 2$ into BamHI - Sall vector from $\beta 2(\text{AGS})_6\alpha 4$ produced the $\beta 2(\text{AGS})_6\alpha 4(\text{AGS})_{12}\beta 2(\text{AGS})_6\alpha 4$ tetramer. This concatamer is referred to hereafter as $\beta 2\text{-}\alpha 4\text{-}\beta 2\text{-}\alpha 4$. cRNAs from linearized cDNA templates were synthesized in vitro using the SP6 mMessage mMachine kit (Ambion, Austin, TX). All chemicals were purchased from Sigma-Aldrich (St. Louis, MO), unless otherwise noted.

Oocyte Removal and Injection. Oocytes were removed surgically from *X. laevis* and placed in a solution containing 82.5 mM NaCl, 2 mM KCl, 1 mM MgCl_2 , 5 mM HEPES, at pH 7.5. They were defolliculated in this buffer containing 2 mg/ml collagenase type IA (Sigma, St. Louis, MO) for 1.5 h. After defolliculation, oocytes were incubated at 18°C in semisterile L-15 medium (Invitrogen, Carlsbad, CA) diluted by half in 10 mM HEPES buffer with 10 U/ml penicillin and 10 $\mu\text{g}/\text{ml}$ streptomycin, pH 7.5.

Oocytes were injected with 5 ng of the $\beta 2\text{-}\alpha 4\text{-}\beta 2\text{-}\alpha 4$ concatamer cRNA and 2.5 ng of $\alpha 5$ cRNA. $(\alpha 3\beta 2)_2\alpha 5$ or $(\alpha 3\beta 4)_2\alpha 5$ AChRs were expressed using free subunits: 3 ng of $\alpha 3$, 3 ng of $\beta 2$ or $\beta 4$, and 6 ng of $\alpha 5$. Function was assayed 4-6 days after injection of cRNAs. Oocytes were voltage clamped at -50mV. Current amplitudes were normalized to maximum ACh responses and averaged for 4 to 5 oocytes.

MOL #66357

Electrophysiological Recordings and Data Analysis. Four to six days after injection, whole-cell membrane currents evoked by ACh were recorded in oocytes at room temperature (~22°C) with a standard two-electrode voltage-clamp amplifier (Oocyte Clamp OC-725; Warner Instrument, Hamden, CT). All recordings were performed at a holding potential of -50 mV. All perfusion solutions contained 0.5 μM atropine to block responses of endogenous muscarinic AChRs that might be present in oocytes. Agonists were applied by means of a set of 2-mm glass tubes directed to the animal pole of the oocytes.

The “Ca⁺⁺ only” currents measured in response to 10 μM ACh for (α4β2)₂α5 and (α3β2)₂α5 or 1000 μM for (α3β4)₂α5 reflect only Ca⁺⁺ flow through AChR channels. The maximum ACh responses were normalized to the peak currents induced in a Cl⁻ free version of normal ND-96 buffer composed of 90 mM NaOH, 2.5 mM KOH, 1.8 mM Ca(OH)₂ and 10 mM HEPES buffered with methanesulfonic acid to pH 7.3. Intracellular electrodes in this case were filled with 2.1 M potassium methanesulfonate. The “Ca⁺⁺ only” solution was composed of 1.8 mM Ca(OH)₂ adjusted to pH 7.5 with HEPES as well as 178 mM dextrose to preserve osmolarity. Data are means ±S.E. for 5 oocytes for each AChR subtype.

The Hill equation was fitted to the concentration-response relationship using a nonlinear least-squares error curve-fit method (Kaleidagraph; Synergy Software, Reading, PA): $I(x) = I_{\max} [x^n / (x^n + EC_{50}^n)]$, where $I(x)$ is the peak current measured at the agonist concentration x , I_{\max} is the maximal current peak at the saturating agonist concentration, EC_{50} is the agonist concentration required for the half-maximal response, and n is the Hill coefficient.

Cell Culture. The HEK tsA201 cell lines expressing human (α4β2)₂α5, (α3β2)₂α5, or (α3β4)₂α5 AChRs were described previously (Wang et al., 1998; Kuryatov et al., 2008). All cell lines were maintained in Dulbecco's modified Eagle's medium (high glucose; Invitrogen, Carlsbad, CA) supplemented with 10% fetal bovine serum (Hyclone, Logan, UT), 100 units/ml

MOL #66357

penicillin, 100 µg/ml streptomycin, and 2 mM L-glutamine (Invitrogen) at 37°C, 5% CO₂ at saturating humidity.

FLEXstation Experiments. AChR function was determined in the cell lines using a FLEXstation II (Molecular Devices, Sunnyvale, CA) bench-top scanning fluorometer as described by Kuryatov et al. (2005). The day before the experiment, cells were plated at 100,000/well on black-walled/clear-bottomed 96-well plates (Costar, Coning, NY). The membrane potential kit (Molecular Devices, Sunnyvale, CA) was used according to the manufacturer's protocol. Serial dilutions of drugs were prepared in V-shaped 96-well plates (Fisher Scientific Co., Pittsburgh, PA) and were added in separate wells. Each point on the curves represents the average of four peak responses from different wells.

Statistics. Data sets are expressed as means ± S.E. Statistical significance between data was determined by Student's *t* test. Differences were considered significant at the level of $p \leq 0.05$.

MOL #66357

Results

Conductance and Agonist Sensitivities of $\alpha 5$ Variants in $\alpha 3^*$ and $\alpha 4^*$ AChRs

Expressed in *Xenopus* Oocytes.

The $\alpha 5$ subunit variant N398 causes reduced Ca^{++} permeability in $(\alpha 4\beta 2)_2\alpha 5$ AChRs, but not in $(\alpha 3\beta 2)_2\alpha 5$ or $(\alpha 3\beta 4)_2\alpha 5$ AChRs (Fig. 1). Human AChR subunit mRNAs were expressed in *Xenopus* oocytes and responses assayed electrophysiologically under voltage clamp conditions. Concatameric $\beta 2$ - $\alpha 4$ - $\beta 2$ - $\alpha 4$ subunits plus free $\alpha 5$ were used in order to insure homogeneous populations of $(\alpha 4\beta 2)_2\alpha 5$ AChRs, free of any contamination with high agonist sensitivity low Ca^{++} permeability $(\alpha 4\beta 2)_2\beta 2$ or low agonist sensitivity high Ca^{++} permeability $(\alpha 4\beta 2)_2\alpha 4$ AChR subtypes (Tapia et al., 2007). The $\alpha 5$ accessory subunits, either the D398 allele or the N398 risk allele, were added in equal molar ratio to the concatamer. The concatamer alone at these concentrations gives virtually no response. For $\alpha 3^*$ AChRs, free subunits were used in a 1:1:2 ratio of $\alpha 3$: β : $\alpha 5$, with the excess $\alpha 5$ intended to insure that all of the AChRs had the subunit composition $(\alpha 3\beta)_2\alpha 5$. The currents provoked by a saturating concentration of ACh were measured in solutions lacking Cl^- to eliminate currents through Cl^- channels. Both a conventional cation mix and a solution containing only Ca^{++} were used. The relative response was calculated as the ACh-induced current observed with Ca^{++} as the only cation as a percent of the current in the normal cation mix. Ca^{++} permeabilities of both $(\alpha 3\beta 2)_2\alpha 5$ and $(\alpha 4\beta 2)_2\alpha 5$ subtypes were quite high. The $\alpha 5$ D398N variation affected only $(\alpha 4\beta 2)_2\alpha 5$ and not $(\alpha 3\beta 2)_2\alpha 5$. $(\alpha 4\beta 2)_2\alpha 5$ N398 had 40% lower Ca^{++} permeability than $(\alpha 4\beta 2)_2\alpha 5$ D398.

The $\alpha 5$ D398N variation did not alter sensitivity to activation by agonists (Fig. 2). $(\alpha 4\beta 2)_2\alpha 5$ AChRs in the $\alpha 5$ D398 and $\alpha 5$ N398 forms were equally sensitive, respectively, to ACh ($\text{EC}_{50} = 1.64 \pm 0.06$ or $1.44 \pm 0.09 \mu\text{M}$), nicotine ($\text{EC}_{50} = 0.499 \pm 0.063$ or 0.640 ± 0.115

MOL #66357

μM), or varenicline ($\text{EC}_{50} = 0.0235 \pm 0.0059$ or $0.0440 \pm 0.0098 \mu\text{M}$)($p=0.32$). $(\alpha 3\beta 2)_2\alpha 5$ AChRs in the $\alpha 5$ D398 and N398 forms were equally sensitive, respectively, to ACh ($\text{EC}_{50} = 1.83 \pm 0.07$ or $1.70 \pm 0.09 \mu\text{M}$). Similarly, the $\alpha 5$ D398 and N398 forms of $(\alpha 3\beta 4)_2\alpha 5$ AChRs were equally sensitive to ACh ($\text{EC}_{50} = 122 \pm 17 \mu\text{M}$ or $115 \pm 20 \mu\text{M}$).

Acute desensitization varied greatly between $(\alpha 4\beta 2)_2\alpha 5$, $(\alpha 3\beta 2)_2\alpha 5$, and $(\alpha 3\beta 4)_2\alpha 5$ AChR subtypes. The D398N variation in $\alpha 5$ had an effect only in the $(\alpha 4\beta 2)_2\alpha 5$ subtype (Fig. 2, Table 1). With the $(\alpha 4\beta 2)_2\alpha 5$ subtype, over three seconds $3 \mu\text{M}$ ACh caused 22% desensitization with respect to the peak response with the D398 variant, but 46% desensitization with the N398 variant. Thus, there is a significant ($p=0.015$) difference in acute desensitization of this subtype between the two $\alpha 5$ variants. The apparent extent of desensitization of the $(\alpha 3\beta 2)_2\alpha 5$ subtype under the same conditions was much greater (86.9% for D398), with little difference between $\alpha 5$ variants (89.7% for N398). The faster and more extensive desensitization of the $(\alpha 3\beta 2)_2\alpha 5$ subtype would cause the integrated currents mediated by this subtype to be much less than those of the $(\alpha 4\beta 2)_2\alpha 5$ subtype. Thus, with presynaptic AChRs tonically activated to promote transmitter release, $(\alpha 4\beta 2)_2\alpha 5$ AChRs would have a much larger effect than $(\alpha 3\beta 2)_2\alpha 5$ AChRs. Another striking subtype-specific difference of $\alpha 3\beta 2$ from $\alpha 4\beta 2$ or $\alpha 3\beta 4$ AChRs is that nicotine causes channel block of $\alpha 3\beta 2$ AChRs, resulting in it behaving as a partial agonist (Rush et al., 2002). The apparent extent of desensitization of the $(\alpha 3\beta 4)_2\alpha 5$ subtype at 3 seconds after $100 \mu\text{M}$ ACh (which similarly approximates the EC_{50} for this lower sensitivity subtype) is only 8-15%.

Sensitivities to Activation and Desensitization by Sustained Exposure to Nicotine of $(\alpha 4\beta 2)_2\alpha 5$, $(\alpha 3\beta 2)_2\alpha 5$, and $(\alpha 3\beta 4)_2\alpha 5$ AChRs Expressed in Permanently Transfected Cell Lines.

Smokers sustain concentrations of nicotine $\leq 0.2 \mu\text{M}$ in their blood for many hours (Benowitz, 1996). Under these conditions sensitive AChR subtypes may be substantially

MOL #66357

desensitized, while less sensitive subtypes may be effected little by such low concentrations of nicotine. Permanently transfected cell lines are better for studies of prolonged desensitization than are oocytes because many parallel cultures can be treated with nicotine for hours to achieve the equilibrium desensitization expected in vivo from exposure to sustained concentrations of nicotine. We have prepared permanently transfected human HEK cell lines which express $(\alpha 4\beta 2)_2\alpha 5$, $(\alpha 3\beta 2)_2\alpha 5$, and $(\alpha 3\beta 4)_2\alpha 5$ AChRs using the D398 $\alpha 5$ variant and used these to compare the effects of activation and desensitization by nicotine on these subtypes (Figure 3). The similar acute activation and desensitization properties of AChR subtypes with the N398 $\alpha 5$ variant for the $(\alpha 3\beta 2)_2\alpha 5$ and $(\alpha 3\beta 4)_2\alpha 5$ subtypes suggest that this variation would not alter the fundamental subtype desensitization properties associated with prolonged exposure to nicotine. Future studies using the $(\alpha 4\beta 2)_2\alpha 5$ N398 variant might reveal more extensive desensitization in this variant.

The $(\alpha 4\beta 2)_2\alpha 5$ AChR subtype is sensitive to activation by nicotine ($EC_{50} = 0.620 \pm 0.107 \mu\text{M}$) (Figure 3). It is also quite sensitive to desensitization ($IC_{50} = 0.0872 \pm 0.0027 \mu\text{M}$). The overlap between the activation and desensitization curves is shaded. This indicates the range of nicotine concentrations where at equilibrium “smoldering activation” could be sustained as a result of significant activation despite a substantial degree of desensitization of the AChR population. This zone of smoldering activation is approximately centered on $0.2 \mu\text{M}$ nicotine, a concentration typically sustained in smokers’ blood (Benowitz, 1996). The potential amplitude of the smoldering response at each nicotine concentration was calculated by multiplying the relative acute response by the relative response remaining after desensitization. The area beneath this curve at concentrations $\leq 0.2 \mu\text{M}$ nicotine was blackened to indicate the sustained amplitude of response which would be expected from the subtype at nicotine concentrations likely to be sustained in smokers. In the case of $(\alpha 4\beta 2)_2\alpha 5$ AChRs, in the presence of $0.2 \mu\text{M}$ nicotine, sustained smoldering activation equivalent to 9% of the maximum acute response

MOL #66357

would be sustained. This tonic effect on membrane potential or calcium concentration in synaptic endings, where these AChRs modulate transmitter release, might substantially promote transmitter release. Most $\alpha 4\beta 2^*$ AChRs are thought to be located presynaptically (Gotti et al., 2007). The sustained 60% desensitization caused by 0.2 μM nicotine would be likely to substantially impair acute synaptic transmission at synapses where postsynaptic $(\alpha 4\beta 2)_2\alpha 5$ AChRs were required for mediating transmission of patterns of acute signals. If the N398 $\alpha 5$ form produced more extensive desensitization, as suggested by the results shown in figure 2 B and C, and Table 1, this would move the equilibrium desensitization curve shown in figure 3 to the left. The net effects of this would be to narrow the range of potential smoldering activation, reduce the amplitude of smoldering activation, reduce transmitter release potentiated by presynaptic $(\alpha 4\beta 2)_2\alpha 5$ AChRs, and through greater desensitization, more complete block of transmission at synapses where this subtype served a postsynaptic role.

The $(\alpha 3\beta 2)_2\alpha 5$ AChR subtype is 4.7 fold less sensitive to activation ($EC_{50} = 2.91 \pm 0.35 \mu\text{M}$) and 34 fold less sensitive to desensitization ($IC_{50} = 2.92 \pm 0.19 \mu\text{M}$) by nicotine than is the $(\alpha 4\beta 2)_2\alpha 5$ AChR subtype (Figure 3). The overlap between activation and desensitization curves centers around 2 μM nicotine, a concentration unlikely to be reached even transiently in smokers. At 0.2 μM nicotine, the sustained smoldering response of $(\alpha 3\beta 2)_2\alpha 5$ AChRs would be 13% of the maximum acute response.

The $(\alpha 3\beta 4)_2\alpha 5$ AChR subtype is 7.5 fold less sensitive to activation ($EC_{50} = 4.64 \pm 0.18 \mu\text{M}$) and 192 fold less sensitive to desensitization ($IC_{50} = 16.7 \pm 0.8 \mu\text{M}$) by nicotine than is the $(\alpha 4\beta 2)_2\alpha 5$ AChR subtype (Figure 3). The overlap between activation and desensitization curves is very large, resulting in an extensive range of smoldering activation and a high maximum potential amplitude of smoldering activation. However, the overlap centers around 8 μM , more than 40 times the concentration of nicotine sustained in smokers. Consequently, at 0.2 μM nicotine, a concentration sustained in smokers, there is negligible desensitization or smoldering

MOL #66357

activation. The lack of desensitization means that transmission is unimpaired at autonomic ganglia synapses, where $(\alpha3\beta4)_2\alpha5$ AChRs are a major postsynaptic subtype. The functional roles of $\alpha3^*$ AChRs in the medial habenula, where they are most abundant in brain, are less clear (Gotti et al., 2007). However, the highest transient nicotine concentrations likely to be found in brain would stimulate very little of the maximum potential acute response. $\alpha3^*$ AChRs in lung might be exposed to larger transient concentrations of nicotine.

MOL #66357

Discussion

We observed that the $\alpha 5$ N398 variant had lower Ca^{++} permeability and greater desensitization than the $\alpha 5$ D398 variant in $(\alpha 4\beta 2)_2\alpha 5$ AChRs, but not in $(\alpha 3\beta 2)_2\alpha 5$ or $(\alpha 3\beta 4)_2\alpha 5$ AChRs. $\alpha 3$, $\beta 4$, and $\alpha 5$ subunits are organized sequentially in the genome and expressed together in the major autonomic ganglia postsynaptic AChR subtype $(\alpha 3\beta 4)_2\alpha 5$ (Gotti et al., 2007). All $\alpha 3^*$ AChR subtypes comprise 3.5% of brain AChRs, while $\alpha 4\beta 2^*$ AChR subtypes comprise > 45% (Marks et al., 2010). $\alpha 4\beta 2^*$ AChRs are important for nicotine addiction. Knock out of $\alpha 4$, $\beta 2$, or $\alpha 6$ AChRs prevents nicotine self-administration, and re-expression of the knocked out subunit in the ventral tegmental area restores self administration (Pons et al., 2008). $(\alpha 4\beta 2)_2\alpha 5$ AChRs comprise 10-37% of brain $\alpha 4\beta 2^*$ AChRs in various regions (Brown et al., 2007; Mao et al., 2008). These are primarily presynaptic AChRs that promote the release of various transmitters. Decreased Ca^{++} permeability and increased desensitization in the $\alpha 5$ N398 variant associated with increased risk for tobacco addiction and lung cancer might result in decreased release of a transmitter whose release is modulated by $(\alpha 4\beta 2)_2\alpha 5$ AChRs, e.g. GABA (McClure-Begley et al., 2009). The $\alpha 5$ D398N variation did not alter sensitivity to agonist activation of $\alpha 3^*$ or $\alpha 4^*$ AChRs. This is not surprising, because ACh binding sites are in the extracellular surface, whereas $\alpha 5$ 398 is in the cytoplasmic surface. $\alpha 5$ 398 is not part of the cation channel, which has a major role in determining Ca^{++} permeability (Tapia et al., 2007). However, it is in a cytoplasmic region thought to form access portals to the channel, which have been shown to have large influence on conductance (Hales et al., 2006). Ion selectivity filters have been found throughout the extracellular vestibule of the AChR, and similar considerations may apply to the cytoplasmic vestibule (Sine et al., 2010).

We showed that $(\alpha 4\beta 2)_2\alpha 5$ AChRs are sensitive to activation and desensitization by nicotine concentrations sustained in smokers. Thus, this subtype is likely to be important in

MOL #66357

mediating effects of nicotine. Smoldering activation of $(\alpha4\beta2)_2\alpha5$ AChRs by nicotine concentrations which desensitize a large fraction of these AChRs may contribute significantly to increasing presynaptic Ca^{++} concentrations and depolarization, thereby promoting transmitter release at synapses where tonic activation of this subtype modulates transmitter release. Extensive desensitization of this subtype by nicotine concentrations in smokers would impair transmission at synapses where it served a postsynaptic role. By contrast, $(\alpha3\beta4)_2\alpha5$ AChRs were shown to be very insensitive to activation or desensitization by concentrations of nicotine sustained in smokers. Thus, this subtype is unlikely to be important in mediating effects of nicotine. $(\alpha3\beta2)_2\alpha5$ AChRs exhibited intermediate sensitivities to activation and desensitization. AChR subtypes containing $\alpha5$ in the medial habenula may play roles in the effects of nicotine (Salas et al., 2009).

Genome wide association studies have shown that risk for tobacco addiction and lung cancer are associated not only with the $\alpha5$ N398 variant, but also with variants which reduce the amount of $\alpha5$ expressed (Wang et al., 2009). Reducing the amount of the $(\alpha4\beta2)_2\alpha5$ subtype would compound the loss of function produced by decreased Ca^{++} permeability and increased desensitization.

An $(\alpha4\beta2)_2\alpha5$ AChR-selective positive allosteric modulator (PAM) could compensate for the deficit in function associated with risk for nicotine addiction and lung cancer. Knock out of $\alpha5$ subunits increases nicotine reward and decreases aversion to high doses of nicotine (Jackson et al., 2010). A PAM could provide genetically based personalized medical therapy for those with the $\alpha5$ N398 variant when combined with nicotine replacement therapy using nicotine or varenicline. Such a PAM might also have cognitive enhancing effects on those not at risk. The $\alpha5$ subunit plays a key role in attention circuitry (Bailey et al., 2010). An $\alpha4\beta2\alpha5$ AChR PAM might enhance nicotinic anti-nociception (Jackson et al., 2010). A PAM would specifically enhance the impact of ACh, especially where volume transmission is mediated by low

MOL #66357

concentrations of ACh. The effects of an $(\alpha 4\beta 2)_2\alpha 5$ -selective PAM would differ from those of agonists like nicotine or varenicline, which are much less subtype-selective. More importantly, a primary effect of such high affinity agonist drugs is to desensitize AChRs, thereby blocking the normal ACh effect. Even if smoldering activation of non-desensitized AChRs were produced by agonist drugs to emulate the tonic effects of ACh, desensitization would also block transmission of information inherent in the changes in ACh concentration produced by changes in the firing rates of cholinergic neurons (Sarter et al., 2009). By contrast, a PAM would leave this information intact and amplify it.

PAMs have been discovered that are selective for AChR subtypes (Bertrand and Gopalakrishnan, 2007). For example, PNU 120596 is highly selective and potent on $\alpha 7$ AChRs (Hurst et al., 2005; Young et al., 2008). Remarkably, it can activate completely desensitized AChRs. Galanthamine is a weak PAM on many AChR subtypes (Samochocki et al., 2003). We found that it was relatively selective for $(\alpha 4\beta 2)_2\alpha 5$ AChRs, using cell lines that express this subtype and other $\alpha 4\beta 2^*$ human AChR subtypes (Kuryatov et al., 2008). It is very likely that potent PAMs selective for $(\alpha 4\beta 2)_2\alpha 5$ AChRs can be discovered. The unique interface between $\alpha 5$ and $\alpha 4$ subunits, or the interface between $\beta 2$ and $\alpha 5$ subunits, are sites at which such PAMs might be directed. Benzodiazepines, which act as PAMs on GABA_A receptors, bind at an $\alpha \gamma$ interface in these receptors (Hanson and Czajkowski et al., 2008). Galanthamine binds at such an interface in ACh binding protein (Hansen and Taylor, 2007). An intrasubunit PAM site on $\alpha 5$, homologous to the $\alpha 7$ -selective transmembrane site for PNU 120596 (Young et al., 2008), could potentiate all $\alpha 5^*$ AChR subtypes, yet perhaps be useful. In any case, the $\alpha 4\beta 2\alpha 5$ cell line used here could be employed with assays using fluorescent indicators of membrane potential in high throughput screens to select for PAMs specific for $(\alpha 4\beta 2)_2\alpha 5$ AChRs.

MOL #66357

A PAM might act by increasing the probability of activation of a liganded AChR, or by reducing desensitization, or both. The effects of a PAM could be analyzed using overlapping dose/response curves for activation and desensitization by nicotine as in Fig. 3. The ideal PAM would effect only the $(\alpha 4\beta 2)_2\alpha 5$ subtype. It would probably shift the activation curve to the left, shift the desensitization curve to the right, or both. The net effect could be to greatly increase the range of overlap of these curves where smoldering activation could take place and increase the amplitude of the maximum response sustained by nicotine. This would result in greater release of transmitters modulated presynaptically by nicotine. Reduced desensitization would reduce impairment of synaptic transmission mediated by postsynaptic $(\alpha 4\beta 2)_2\alpha 5$ AChRs. Both increased activation and decreased desensitization would increase the activation of $(\alpha 4\beta 2)_2\alpha 5$ AChRs by ACh in the absence of nicotine.

MOL #66357

Acknowledgements

We thank Barbara Campling for her comments on the manuscript

MOL #66357

Authorship Contributions

Participated in research design: Lindstrom, Kuryatov.

Conducted experiments: Kuryatov.

Performed data analysis: Kuryatov.

Wrote or contributed to the writing of the manuscript: Lindstrom, Kuryatov, and Berrettini.

Other: Lindstrom and Berrettini acquired funding for the research.

MOL #66357

References

- Amos CI, Wu X, Broderick P, Gorlov IP, Gu J, Eisen T, Dong Q, Zhang Q, Gu X, Vijayakrishnan J, Sullivan K, Matakidou A, Wang Y, Mills G, Doheny K, Tsai YY, Chen WV, Shete S, Spitz MR and Houlston RS (2008) Genome-wide association scan of tag SNPs identifies a susceptibility locus for lung cancer at 15q25.1. *Nat Genet* **40**(5):616-622.
- Bailey CD, De Biasi M, Fletcher PJ and Lambe EK (2010) The nicotinic acetylcholine receptor $\alpha 5$ subunit plays a key role in attention circuitry and accuracy. *J Neurosci* **30**(27):9241-9252.
- Benowitz NL (1996) Pharmacology of nicotine: addiction and therapeutics. *Annu Rev Pharmacol Toxicol* **36**:597-613.
- Berrettini W, Yuan X, Tozzi F, Song K, Francks C, Chilcoat H, Waterworth D, Muglia P and Mooser V (2008) $\alpha 5/\alpha 3$ nicotinic receptor subunit alleles increase risk for heavy smoking. *Mol Psychiatry* **13**(4):368-373.
- Bertrand D and Gopalakrishnan M (2007) Allosteric modulation of nicotinic acetylcholine receptors. *Biochem Pharmacol* **74**(8):1155-1163.
- Bierut LJ, Stitzel JA, Wang JC, Hinrichs AL, Gruzca RA, Xuei X, Saccone NL, Saccone SF, Bertelsen S, Fox L, Horton WJ, Breslau N, Budde J, Cloninger CR, Dick DM, Foroud T, Hatsukami D, Hesselbrock V, Johnson EO, Kramer J, Kuperman S, Madden PA, Mayo K, Nurnberger J, Jr., Pomerleau O, Porjesz B, Reyes O, Schuckit M, Swan G, Tischfield JA, Edenberg HJ, Rice JP and Goate AM (2008) Variants in nicotinic receptors and risk for nicotine dependence. *Am J Psychiatry*.
- Brown RW, Collins AC, Lindstrom JM and Whiteaker P (2007) Nicotinic $\alpha 5$ subunit deletion locally reduces high-affinity agonist activation without altering nicotinic receptor numbers. *J Neurochem* **103**(1):204-215.
- Gerzanich V, Wang F, Kuryatov A and Lindstrom J (1998) $\alpha 5$ subunit alters desensitization, pharmacology, Ca^{++} permeability and Ca^{++} modulation of human neuronal $\alpha 3$ nicotinic receptors. *J Pharmacol Exp Ther* **286**(1):311-320.

MOL #66357

- Gotti C, Moretti M, Gaimarri A, Zanardi A, Clementi F and Zoli M (2007) Heterogeneity and complexity of native brain nicotinic receptors. *Biochem Pharmacol* **74**(8):1102-1111.
- Grady SR, Salminen O, McIntosh JM, Marks MJ and Collins AC (2010) Mouse striatal dopamine nerve terminals express $\alpha 4\alpha 5\beta 2$ and two stoichiometric forms of $\alpha 4\beta 2^*$ -nicotinic acetylcholine receptors. *J Mol Neurosci* **40**(1-2):91-95.
- Hales TG, Dunlop JI, Deeb TZ, Carland JE, Kelley SP, Lambert JJ and Peters JA (2006) Common determinants of single channel conductance within the large cytoplasmic loop of 5-hydroxytryptamine type 3 and $\alpha 4\beta 2$ nicotinic acetylcholine receptors. *J Biol Chem* **281**(12):8062-8071.
- Hansen SB and Taylor P (2007) Galanthamine and non-competitive inhibitor binding to ACh-binding protein: evidence for a binding site on non- α -subunit interfaces of heteromeric neuronal nicotinic receptors. *J Mol Biol* **369**(4):895-901.
- Hanson SM and Czajkowski C (2008) Structural mechanisms underlying benzodiazepine modulation of the GABA_A receptor. *J Neurosci* **28**(13):3490-3499.
- Hung RJ, McKay JD, Gaborieau V, Boffetta P, Hashibe M, Zaridze D, Mukeria A, Szeszenia-Dabrowska N, Lissowska J, Rudnai P, Fabianova E, Mates D, Bencko V, Foretova L, Janout V, Chen C, Goodman G, Field JK, Liloglou T, Xinarianos G, Cassidy A, McLaughlin J, Liu G, Narod S, Krokan HE, Skorpén F, Elvestad MB, Hveem K, Vatten L, Linseisen J, Clavel-Chapelon F, Vineis P, Bueno-de-Mesquita HB, Lund E, Martínez C, Bingham S, Rasmuson T, Hainaut P, Riboli E, Ahrens W, Benhamou S, Laggiou P, Trichopoulos D, Holcatova I, Merletti F, Kjaerheim K, Agudo A, Macfarlane G, Talamini R, Simonato L, Lowry R, Conway DI, Znaor A, Healy C, Zelenika D, Boland A, Delepine M, Foglio M, Lechner D, Matsuda F, Blanche H, Gut I, Heath S, Lathrop M and Brennan P (2008) A susceptibility locus for lung cancer maps to nicotinic acetylcholine receptor subunit genes on 15q25. *Nature* **452**(7187):633-637.
- Hurst RS, Hajos M, Raggenbass M, Wall TM, Higdon NR, Lawson JA, Rutherford-Root KL, Berkenpas

MOL #66357

- MB, Hoffmann WE, Piotrowski DW, Groppi VE, Allaman G, Ogier R, Bertrand S, Bertrand D and Arneric SP (2005) A novel positive allosteric modulator of the $\alpha 7$ neuronal nicotinic acetylcholine receptor: in vitro and in vivo characterization. *J Neurosci* **25**(17):4396-4405.
- Jackson KJ, Marks MJ, Vann RE, Chen X, Gamage TF, Warner JA and Damaj MI (2010) Role of $\alpha 5$ nicotinic acetylcholine receptors in pharmacological and behavioral effects of nicotine in mice. *J Pharmacol Exp Ther* **334**(1):137-146.
- Kuryatov A, Luo J, Cooper J and Lindstrom J (2005) Nicotine acts as a pharmacological chaperone to up-regulate human $\alpha 4\beta 2$ acetylcholine receptors. *Mol Pharmacol* **68**(6):1839-1851.
- Kuryatov A, Onksen J and Lindstrom JM (2008) Roles of accessory subunits in $\alpha 4\beta 2$ * nicotinic receptors. *Mol Pharmacol*. **74**:132-143
- Mao D, Perry DC, Yasuda RP, Wolfe BB and Kellar KJ (2008) The $\alpha 4\beta 2\alpha 5$ nicotinic cholinergic receptor in rat brain is resistant to up-regulation by nicotine in vivo. *J Neurochem* **104**(2):446-456.
- Marks MJ, Laverty DS, Whiteaker P, Salminen O, Grady SR, McIntosh JM and Collins AC (2010) John Daly's compound, epibatidine, facilitates identification of nicotinic receptor subtypes. *J Mol Neurosci* **40**(1-2):96-104.
- McClure-Begley TD, King NM, Collins AC, Stitzel JA, Wehner JM and Butt CM (2009) Acetylcholine-stimulated [3 H]GABA release from mouse brain synaptosomes is modulated by $\alpha 4\beta 2$ and $\alpha 4\alpha 5\beta 2$ nicotinic receptor subtypes. *Mol Pharmacol* **75**(4):918-926.
- Pons S, Fattore L, Cossu G, Tolu S, Porcu E, McIntosh JM, Changeux JP, Maskos U and Fratta W (2008) Crucial role of $\alpha 4$ and $\alpha 6$ nicotinic acetylcholine receptor subunits from ventral tegmental area in systemic nicotine self-administration. *J Neurosci* **28**(47):12318-12327.
- Rush R, Kuryatov A, Nelson ME and Lindstrom J (2002) First and second transmembrane segments of $\alpha 3$, $\alpha 4$, $\beta 2$, and $\beta 4$ nicotinic acetylcholine receptor subunits influence the efficacy and potency of nicotine. *Mol Pharmacol* **61**(6):1416-1422.

MOL #66357

- Saccone NL, Saccone SF, Hinrichs AL, Stitzel JA, Duan W, Pergadia ML, Agrawal A, Breslau N, Grucza RA, Hatsukami D, Johnson EO, Madden PA, Swan GE, Wang JC, Goate AM, Rice JP and Bierut LJ (2009) Multiple distinct risk loci for nicotine dependence identified by dense coverage of the complete family of nicotinic receptor subunit (CHRN) genes. *Am J Med Genet B Neuropsychiatr Genet* **150B**(4):453-466.
- Salas R, Sturm R, Boulter J and De Biasi M (2009) Nicotinic receptors in the habenulo-interpeduncular system are necessary for nicotine withdrawal in mice. *J Neurosci* **29**(10):3014-3018.
- Samochocki M, Hoffle A, Fehrenbacher A, Jostock R, Ludwig J, Christner C, Radina M, Zerlin M, Ullmer C, Pereira EF, Lubbert H, Albuquerque EX and Maelicke A (2003) Galantamine is an allosterically potentiating ligand of neuronal nicotinic but not of muscarinic acetylcholine receptors. *J Pharmacol Exp Ther* **305**(3):1024-1036.
- Sarter M, Parikh V and Howe WM (2009) Phasic acetylcholine release and the volume transmission hypothesis: time to move on. *Nat Rev Neurosci* **10**(5):383-390.
- Sine SM, Wang HL, Hansen S and Taylor P (2010) On the origin of ion selectivity in the Cys-loop receptor family. *J Mol Neurosci* **40**(1-2):70-76.
- Tapia L, Kuryatov A and Lindstrom J (2007) Ca⁺⁺ permeability of the (α4)₃(β2)₂ stoichiometry greatly exceeds that of (α4)₂(β2)₃ human acetylcholine receptors. *Mol Pharmacol* **71**(3):769-776.
- Thorgeirsson TE, Geller F, Sulem P, Rafnar T, Wiste A, Magnusson KP, Manolescu A, Thorleifsson G, Stefansson H, Ingason A, Stacey SN, Bergthorsson JT, Thorlacius S, Gudmundsson J, Jonsson T, Jakobsdottir M, Saemundsdottir J, Olafsdottir O, Gudmundsson LJ, Bjornsdottir G, Kristjansson K, Skuladottir H, Isaksson HJ, Gudbjartsson T, Jones GT, Mueller T, Gottsater A, Flex A, Aben KK, de Vegt F, Mulders PF, Isla D, Vidal MJ, Asin L, Saez B, Murillo L, Blondal T, Kolbeinsson H, Stefansson JG, Hansdottir I, Runarsdottir V, Pola R, Lindblad B, van Rij AM, Dieplinger B, Haltmayer M, Mayordomo JI, Kiemenev LA, Matthiasson SE, Oskarsson H, Tyrfingsson T, Gudbjartsson DF, Gulcher JR, Jonsson S, Thorsteinsdottir U, Kong A and Stefansson K (2008) A variant associated with nicotine dependence, lung cancer and peripheral

MOL #66357

arterial disease. *Nature* **452**(7187):638-642.

Wang F, Nelson ME, Kuryatov A, Olale F, Cooper J, Keyser K and Lindstrom J (1998) Chronic nicotine treatment up-regulates human $\alpha 3\beta 2$ but not $\alpha 3\beta 4$ acetylcholine receptors stably transfected in human embryonic kidney cells. *J Biol Chem* **273**(44):28721-28732.

Wang JC, Cruchaga C, Saccone NL, Bertelsen S, Liu P, Budde JP, Duan W, Fox L, Gruzca RA, Kern J, Mayo K, Reyes O, Rice J, Saccone SF, Spiegel N, Steinbach JH, Stitzel JA, Anderson MW, You M, Stevens VL, Bierut LJ and Goate AM (2009) Risk for nicotine dependence and lung cancer is conferred by mRNA expression levels and amino acid change in CHRNA5. *Hum Mol Genet* **18**(16):3125-3135.

Weiss RB, Baker TB, Cannon DS, von Niederhausern A, Dunn DM, Matsunami N, Singh NA, Baird L, Coon H, McMahon WM, Piper ME, Fiore MC, Scholand MB, Connett JE, Kanner RE, Gahring LC, Rogers SW, Hoidal JR and Leppert MF (2008) A candidate gene approach identifies the CHRNA5-A3-B4 region as a risk factor for age-dependent nicotine addiction. *PLoS Genetics* **4**(7):1-11

Xu W, Gelber S, Orr-Urtreger A, Armstrong D, Lewis RA, Ou CN, Patrick J, Role L, De Biasi M and Beaudet AL (1999) Megacystis, mydriasis, and ion channel defect in mice lacking the $\alpha 3$ neuronal nicotinic acetylcholine receptor. *Proc Natl Acad Sci U S A* **96**(10):5746-5751.

Young GT, Zwart R, Walker AS, Sher E and Millar NS (2008) Potentiation of $\alpha 7$ nicotinic acetylcholine receptors via an allosteric transmembrane site. *Proc Natl Acad Sci U S A* **105**(38):14686-14691.

Zhou Y, Nelson ME, Kuryatov A, Choi C, Cooper J and Lindstrom J (2003) Human $\alpha 4\beta 2$ acetylcholine receptors formed from linked subunits. *J Neurosci* **23**(27):9004-9015.

MOL #66357

Footnotes

This work was supported by grant NS11323 and by grant DA025201 from the National Institutes of Health.

MOL #66357

Legends for Figures

Fig. 1. $\alpha 5$ N398 exhibited lower Ca^{++} permeability than $\alpha 5$ D398 in $(\alpha 4\beta 2)_2\alpha 5$ AChRs, but this variation had no effect on Ca^{++} permeabilities of $\alpha 3^*$ AChRs. Human AChRs were expressed in *Xenopus* oocytes. $(\alpha 4\beta 2)_2\alpha 5$ AChRs were expressed using a tetrameric concatamer $\beta 2$ - $\alpha 4$ - $\beta 2$ - $\alpha 4$ plus free $\alpha 5$ subunits. $\alpha 3^*$ AChR subtypes used all free subunits. The relative response is the current obtained using 1.8 mM Ca^{++} as the sole cation compared to the current obtained using a buffer containing 90 mM Na^+ , 2.5 mM K^+ and 1.8 mM Ca^{++} . Thus, currents reflect only Ca^{++} flow through AChRs. Maximum responses were obtained using 10 μM ACh for the sensitive $(\alpha 3\beta 2)_2\alpha 5$ and $(\alpha 4\beta 2)_2\alpha 5$ subtypes and 1,000 μM ACh for the less sensitive $(\alpha 3\beta 4)_2\alpha 5$ subtype.

Fig. 2. Assay of effects of the $\alpha 5$ D398N variation on sensitivity to activation by ACh and acute desensitization of the $(\alpha 4\beta 2)_2\alpha 5$, $(\alpha 3\beta 2)_2\alpha 5$, and $(\alpha 3\beta 4)_2\alpha 5$ AChR subtypes. Human AChRs were expressed in *Xenopus* oocytes as in Fig. 1. The $(\alpha 4\beta 2)_2\alpha 5$ subtype is shown in A, B, C. A) Shows that there is no significant difference in sensitivity to activation by ACh between the two $\alpha 5$ variants. Each response is the average of 4-5 oocytes. B, C) Show the kinetics of acute desensitization in a single oocyte expressing each variant exposed to some of the ACh concentrations used in the dose/response curve. The averaged desensitization of 4-5 oocytes at 3 seconds after application of ACh are shown in table 1, revealing that the N variant desensitizes significantly more. The responses in the dose response curve were the peak responses. The $(\alpha 3\beta 2)_2\alpha 5$ subtype is shown in D, E, F. D) Shows that there is no significant difference in sensitivity to activation between the two $\alpha 5$ variants. E, F) Show the kinetics of desensitization. It is much faster and more extensive than in $(\alpha 4\beta 2)_2\alpha 5$ AChRs. The extent of desensitization by the two $\alpha 5$ variants in the $(\alpha 3\beta 2)_2\alpha 5$ subtype is not significant, as shown in

MOL #66357

table 1. The $(\alpha 3\beta 4)_2\alpha 5$ subtype is shown in G, H, I. G) Shows that there is no significant difference in sensitivity to activation between the two $\alpha 5$ variants. H, I) Show the kinetics of desensitization. It is slower and less extensive than in $(\alpha 3\beta 2)_2\alpha 5$ AChRs. The extent of desensitization by the two $\alpha 5$ variants is not significant, as shown in table 1.

Fig. 3. Nicotine sensitivities differ dramatically between the $(\alpha 4\beta 2)_2\alpha 5$, $(\alpha 3\beta 2)_2\alpha 5$, and $(\alpha 3\beta 4)_2\alpha 5$ subtypes. Human AChRs were expressed in permanently transfected human embryonic kidney cell lines (Wang et al., 1998; Kuryatov et al., 2008). Responses were assayed in microwell cultures using a Flexstation microplate fluorometer and a fluorescent probe sensitive to membrane potential. Desensitization was measured after 1.5 hours. This allows enough time for equilibrium desensitization but not enough time for upregulated AChRs to be expressed on the cell surface. The fraction of AChRs remaining activatable after desensitization was assayed using 1 mM ACh. The overlapping region between concentration/response curves for desensitization and activation is designated in gray. This is the concentration range in which AChRs remaining undesensitized could undergo smoldering activation. The potential smoldering response at each concentration of nicotine was calculated by multiplying the acute response to nicotine at that concentration by the fractional response remaining after desensitization. The area under the smoldering response curve below 0.2 μ M was blackened to indicate the range of responses that might be sustained in smokers.

MOL #66357

Table 1 Effect of $\alpha 5$ D398N Variants on Extent of Acute Desensitization

AChR Subtype	Extent of Acute Desensitization (%)
$(\alpha 4\beta 2)_2\alpha 5$ D	22.1 ± 3.3
N	46.0 ± 4.6
$(\alpha 3\beta 2)_2\alpha 5$ D	86.9 ± 2.2
N	89.7 ± 3.3
$(\alpha 3\beta 4)_2\alpha 5$ D	15.2 ± 6.9
N	8.0 ± 4.6

} p = 0.015

Using ACh concentrations that approximate the EC₅₀ values for each subtype (3 μM for $(\alpha 4\beta 2)_2\alpha 5$ and $(\alpha 3\beta 2)_2\alpha 5$, 100 μM for $(\alpha 3\beta 4)_2\alpha 5$) the percent desensitization at 3 seconds after the application of ACh was calculated by comparing the peak current to the current after 3 seconds. Each value is the average of 4-5 oocytes. The extent of desensitization was significantly different between the D398N variants only in the case of the $(\alpha 4\beta 2)_2\alpha 5$ subtype.




Figure 1




Figure 2






Figure 3